Poop pills vs antibiotics: new hope for stubborn gut infections?
NCT ID NCT05266807
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether fecal microbiota transplantation (FMT) capsules, made from healthy donor stool, can prevent C. diff infection from coming back better than standard antibiotics. About 100 adults with a first or first-recurrent C. diff infection will get either antibiotics alone or antibiotics followed by FMT capsules. The main goal is to see who stays infection-free for 8 weeks after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fecal microbiota transplantation (FMT) capsules from healthy donors
- What this could lead to
- If successful, this could offer a safer, more effective way to prevent C. diff from coming back, reducing the need for repeated antibiotics.
- What could go wrong
- This is a relatively small Phase 3 trial (100 people), and FMT is still experimental. It may not work better than antibiotics, and there are unknown risks from donor stool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults (≥18 years old) at the time of informed consent 2. Informed consent signature 3. Medical record documentation of CDI defined as: a. A first CDI episode associated with risks factors for recurrence, defined as: i. No CDI episode within the last 8 weeks ii. Current combination of CDI signs and symptoms, confirmed by medical record documentation of microbiological evidence of C. difficile toxin and C. difficile in stools shown by a CDI PCR positive test with Ct \< 25 or a toxin A/B EIA positive test and without reasonable evidence of another cause of diarrhea, iii. Presenting at least one of the following risks factors for CDI recurrence: * age \>65 years-old, * hospitalization within the last 3 months, * use of proton pump inhibitors (PPI) within the last 3 months, * Charlson comorbidity index (CCI) \>2, * living in long term facility, * healthcare- associated CDI (see definition in section 7), * severe CDI episode (see definitions in section 6.1.2), * immunocompromised patient (except severely immunocompromised according to definitions in section 7.1), * history of prior CDI episode(s) (more than 8 weeks ago). OR b. A first CDI recurrence, defined as: i. Previous episode of treated and cured CDI within the last 8 weeks confirmed by medical record documentation of a clinical picture of CDI combined with a positive microbiological CDI test performed according to CDI diagnosis ESCMID guidelines ii. Current combination of CDI signs and symptoms, confirmed by medical record documentation of microbiological evidence of C. difficile toxin and C. difficile in stools shown by a CDI PCR positive test with Ct \< 25 or a toxin A/B EIA positive test , and without reasonable evidence of another cause of diarrhea.. 4. No multiple episodes (no more than 2 CDI episodes) within 3 last months. 5. Already taking since less than 10 days or will start a course of antibiotics (vancomycin or fidaxomicin) to control recurrent CDI symptoms at the time of screening. 6. Willing and able to have FMT by capsule Exclusion Criteria: 1. Severe-complicated CDI if at least one of the following signs or symptoms are: * ongoing at time of screening and related to CDI: hypotension, septic shock, elevated serum lactate, ileus, * or were present at any time of the CDI episode and related to CDI: toxic megacolon, bowel perforation, or any fulminant course of disease (i.e. rapid deterioration of the patient. 2. Prior FMT within 6 months of randomization, 3. Prior total colectomy, colostomy, ileostomy, or gastrectomy 4. Metronidazole already given alone for the treatment of the current CDI for more than 3 days, 5. Need for continued non-anti-CDI systemic antibiotics (should be stopped at randomization at the latest), except prophylactic doses of trimethoprim/sulfamethoxazole, 6. Anticipated indication for antibiotics treatment (for a non-CDI reason) in the next 8 weeks except prophylactic doses of trimethoprim/sulfamethoxazole 7. Other causes of chronic or acute diarrhea beyond CDI (chronic diarrhea is defined as loose/watery stools, which occur three or more times within 24 hours and last for 4 or more weeks) 8. Inflammatory bowel disease, 9. Patients with swallowing disorders, Zenker's diverticulum, gastroparesis, or prior small bowel obstruction, 10. Known hypersensitivity to vancomycin or fidaxomicin, 11. Pregnant/lactating women, 12. Estimated patient's life expectancy of less than 10 weeks, 13. Inability to follow protocol study procedures, 14. Inability to give informed consent, 15. Any condition or medications that will put the participant at greater risk from FMT according to the investigator, 16. Severely immunocompromised 17. No response to anti-CDI antibiotic treatment after at least 5 days of treatment (i.e. no diminution of the daily number of stools at BSS 6-7 compared to first day of treatment; or worsening of CDI severity parameters)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clostridioides difficile infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
8 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHUV
RECRUITINGLausanne, Canton of Vaud, 1011, Switzerland
-
HFR Fribourg - Hôpital cantonal
RECRUITINGFribourg, Canton of Fribourg, 1708, Switzerland
-
Hirslanden Klinik St Anna
RECRUITINGLucerne, Canton of Lucerne, 6006, Switzerland
-
Inselspital Bern
RECRUITINGBern, Canton of Bern, 3010, Switzerland
-
Institut central des hôpitaux
RECRUITINGSion, Valais, 1950, Switzerland
-
Kantonsspital St Gallen, HOCH
RECRUITINGSankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Universitätsspital
RECRUITINGBasel, Basel, 4031, Switzerland
-
Universitätsspital Zürich
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a potato starch shake off Drug-Resistant gut bacteria?
- Your dinner plate might fight c. diff: diet study aims to stop repeat infections
- FMT vs antibiotics: which works better Long-Term for c. diff?
- Hospital maps may slash infection spread
- New antibiotic CRS3123 takes on c. diff in early trial
- Gut bacteria capsules take on superbugs in antibiotic patients